Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Byrna Technologies Inc (BYRN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Byrna Technologies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Byrna Technologies Inc trades at $6.02 (market cap $139.06M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 32.3× Byrna Technologies Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BYRN | |
|---|---|---|
Market Cap | $4.49B | $139.06M |
Sector | Health | Technology |
52-Week High | $28.06 | $32.30 |
52-Week Low | $20.06 | $4.96 |
Enterprise Value | $3.69B | $132.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BYRN trades at $7.08, up 1.58% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The company reported Q4 2025 EPS beat but a Q1 2026 miss, with revenue of $118.12M in 2025 and a net income margin of 7.3%. Recent news highlights strategic marketing expansions and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic given strong analyst buy ratings (71.4%) and a high price target upside, though risks include negative cash flow, ongoing legal investigations, and margin pressure from retail channel shifts. Earnings growth and successful execution of new initiatives are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →
